ArticleJournal of the science of food and agriculture2026
Bio-guided fractionation of (9Z )-5,8,11-trihydroxyoctadec-9-enoic acid from Abelmoschus sagittifolius root as a potent α-glucosidase inhibitor: An integrated in vitro and in silico study.
Article in Journal of the science of food and agriculture, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbelmoschus sagittifolius stands out as a valuable medicinal source for developing functional food targeting type 2 diabetes. This study investigated the α-glucosidase inhibitory potential of an active fraction obtained from A. sagittifolius roots (ASR), enriched in (9Z)-5,8,11-trihydroxyoctadec-9-enoic acid (OA), using both enzyme kinetics and molecular docking analyses. The effect of simulated digestion and in silico acute oral toxicity was also evaluated.
resultsThe bioactive fraction, with OA as major component, exhibited strong α-glucosidase inhibitory activity [half-inhibitory concentration (IC
conclusionThis study provides the first investigation into the potential of an OA enriched fraction and its inhibitory mechanism, highlighting OA as a promising bioactive compound for the development of functional foods or nutraceuticals aimed at managing type 2 diabetes. However, further studies, including enzyme-based validation, toxicity evaluation, bioavailability assessment and clinical investigation, are required to comprehensively confirm the efficacy and safety of OA as a potent α-glucosidase inhibitor. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.